The paucity of candidates in the pipeline for the treatment of depression has been causing concern for some time. However, recent Datamonitor Healthcare analysis has identified five approaches to treating depression, all still at a relatively early stage of investigation, that could revitalize the field in coming years:
Five promising approaches to expand the depression armory
The paucity of candidates in the pipeline for the treatment of depression has been causing concern for some time. However, recent Datamonitor Healthcare analysis has identified five approaches to treating depression, all still at a relatively early stage of investigation, that could revitalize the field in coming years:
More from Neurological
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.